476 related articles for article (PubMed ID: 27263777)
1. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
Ri M
Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
[TBL] [Abstract][Full Text] [Related]
2. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Dou QP; Zonder JA
Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
4. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Dolloff NG
Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
[TBL] [Abstract][Full Text] [Related]
5. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
[TBL] [Abstract][Full Text] [Related]
6. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
[TBL] [Abstract][Full Text] [Related]
7. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma.
Ri M
Int J Hematol; 2016 Sep; 104(3):273-80. PubMed ID: 27169614
[TBL] [Abstract][Full Text] [Related]
8. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
Bai Y; Su X
Asia Pac J Clin Oncol; 2021 Feb; 17(1):29-35. PubMed ID: 32920949
[TBL] [Abstract][Full Text] [Related]
9. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
[TBL] [Abstract][Full Text] [Related]
10. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
11. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
Yu Z; Wei X; Liu L; Sun H; Fang T; Wang L; Li Y; Sui W; Wang K; He Y; Zhao Y; Huang W; An G; Meng F; Huang C; Yu T; Anderson KC; Cheng T; Qiu L; Hao M
EBioMedicine; 2022 Apr; 78():103950. PubMed ID: 35344764
[TBL] [Abstract][Full Text] [Related]
12. [Research Progress on Molecular Mechanisms of Resistance to Bortezomib in Multiple Myeloma- Review].
Shi LL; Zhai YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1576-1579. PubMed ID: 29070146
[TBL] [Abstract][Full Text] [Related]
13. DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma.
Wang Y; Gao S; Chen L; Liu S; Ma J; Cao Z; Li Q
Carcinogenesis; 2022 Dec; 43(11):1030-1038. PubMed ID: 36426924
[TBL] [Abstract][Full Text] [Related]
14. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
16. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
17. [Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma].
Wang YR; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1584-1587. PubMed ID: 37846721
[TBL] [Abstract][Full Text] [Related]
18. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]